In this exclusive report, we take a close look at the global Oral Clinical Nutrition Market. It assesses the role of AI in caloric diagnostics, explores therapeutic mandates driven by reimbursement and shares insights from different regions. The report covers essential aspects like competitive benchmarking, market dynamics and evaluations of innovative disease-specific solutions and ready-to-drink liquid products. The global Oral Clinical Nutrition Market size was valued at US$ 18.32 Billion in 2025 and is poised to grow from US$ 19.02 Billion in 2026 to 29.45 Billion by 2033, growing at a CAGR of 5.36% in the forecast period (2026-2033). This comprehensive analysis examines segment performance across product types, formats, and geographies, with particular attention to emerging opportunities in disease-specific formulations and home-care settings.
Market Size (2026)
$18.32B
Projected (2033)
$29.45B
CAGR
5.36%
Published
April 2026
Select User License
Selected
PDF Report
USD 4,900
USD 3,200
The Oral Clinical Nutrition Market is valued at $18.32B and is projected to grow at a CAGR of 5.36% during 2026 - 2033. North America holds the largest regional share, while Asia-Pacific (6.7%–8.2% CAGR) is the fastest-growing market.
Study Period
2020 - 2033
Market Size (2026)
$18.32B
CAGR (2026 - 2033)
5.36%
Largest Market
North America
Fastest Growing
Asia-Pacific (6.7%–8.2% CAGR)
Market Concentration
Medium
*Disclaimer: Major Players sorted in no particular order
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Global Oral Clinical Nutrition market valued at $18.32B in 2026, projected to reach $29.45B by 2033 at 5.36% CAGR
Key growth driver: Integration of medical nutrition therapy into standard hospital and outpatient care pathways (High, +1.5% CAGR impact)
North America holds the largest market share, while Asia-Pacific (6.7%–8.2% CAGR) is the fastest-growing region
AI Impact: Artificial Intelligence is really changing the Oral Clinical Nutrition Market. It is taking dietary supplements and turning them into personalized nutrition plans that are controlled by Artificial Intelligence.
10 leading companies profiled including Baxter International Inc., Otsuka Holdings Co., Ltd., Mead Johnson & Company, LLC and 7 more
Artificial Intelligence is really changing the Oral Clinical Nutrition Market. It is taking dietary supplements and turning them into personalized nutrition plans that are controlled by Artificial Intelligence. The biggest change is that we can now predict when someone is not getting nutrients and control their blood sugar levels. This is happening because we have systems that use Artificial Intelligence to look at records and test results in real time. These systems can then recommend the amount of protein and carbs for each patient to help them recover.
By 2026 these systems will be able to figure out when patients are getting tired of foods and suggest new ones. This will help patients who are getting treatment for cancer and other diseases to eat calories. Artificial Intelligence is becoming a part of the medical nutrition field. It is helping to make sure that the ingredients used in nutrition products are safe and free from allergens. In 2026 companies will use Artificial Intelligence to look at the structure of ingredients and catch any problems before they start producing products.
Artificial Intelligence will also help hospitals and other institutions get the nutrition products they need when they need them. It will do this by predicting when there will be outbreaks of disease or when more people will need products. Artificial Intelligence is also being used to create models of the gut to test how different nutrients affect it. This will help us create nutrition products that are tailored to each patient's needs. The Oral Clinical Nutrition Market is becoming a leader in the use of Artificial Intelligence and data to create effective treatments.
Artificial Intelligence and the Oral Clinical Nutrition Market are working together to make healthcare better.
The oral clinical nutrition market has shifted gears from being merely a supportive care option to becoming a vital part of proactive therapeutic interventions. Today, we see medical nutrition therapy integrated into standard hospital and outpatient care pathways, where oral nutritional supplements (ONS) play a crucial role in addressing disease-related malnutrition. This transformation is largely influenced by the industry's commitment to improving patient recovery times and minimizing hospital readmissions, particularly for those transitioning from acute care back to their homes.
A notable trend is the increase in disease-specific and condition-focused formulations, which go beyond generic caloric support to deliver targeted metabolic benefits for patients with oncology, diabetes, and renal conditions. Manufacturers are increasingly leveraging AI-driven precision nutrition platforms to tailor macro and micronutrient profiles to individual patient biomarkers and gut microbiome health. The market is also shifting towards better taste and clean-label ingredients, with plant-based protein alternatives and organic sweeteners becoming standard in premium medical nutrition catalogs.
This professionalized environment reflects a market that has matured through strict clinical validation and performance standards linked to reimbursement, establishing oral nutrition as a strategic, data-rich asset for global geriatric health and chronic disease management.
| Year | Market Size (USD Billion) | Period |
|---|---|---|
| 2025 | $18.32B | Historical |
| 2026 | $19.44B | Forecast |
| 2027 | $20.63B | Forecast |
| 2028 | $21.89B | Forecast |
| 2029 | $23.23B | Forecast |
| 2030 | $24.65B | Forecast |
| 2031 | $26.15B | Forecast |
| 2032 | $27.75B | Forecast |
| 2033 | $29.45B | Forecast |
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Base Year: 2025Today, we see medical nutrition therapy integrated into standard hospital and outpatient care pathways, where oral nutritional supplements (ONS) play a crucial role in addressing disease-related malnutrition.
A notable trend is the increase in disease-specific and condition-focused formulations, which go beyond generic caloric support to deliver targeted metabolic benefits for patients with oncology, diabetes, and renal conditions.
Medicare and private insurance companies are now including nutrition therapy in their standard care plans.
Manufacturers are increasingly leveraging AI-driven precision nutrition platforms to tailor macro and micronutrient profiles to individual patient biomarkers and gut microbiome health.
One big issue is that patients do not always take their nutrition supplements as they should. Sometimes they get tired of the taste. Do not like the texture and this can be a problem if they have to take the supplements for a long time.
Different patients have needs so doctors have to be careful when choosing a nutrition product for them. This can make it hard to prescribe the product to all patients.
This can be a problem if they have to take the supplements for a long time.
There are some opportunities in the oral clinical nutrition market. For example companies can make nutrition products that are tailored to diseases, like cancer or diabetes. This can help patients get the nutrition they need to manage their disease. Oral clinical nutrition is also becoming more popular in clinics and at home which means that more people can use these products. When doctors and nutrition companies work together to educate patients about nutrition it can help the oral clinical nutrition market grow. The oral clinical nutrition market is really, about helping patients get the nutrition they need.
That is why it is so important.
| Region | Market Share | Growth Rate |
|---|---|---|
| North America | 22.8% | 5.5%–6.4%% CAGR |
| Europe | 20.6% | 4.5%–6.2%% CAGR |
| Asia Pacific | 16.4% | 6.7%–8.2%% CAGRFastest |
| Latin America | 20.1% | 6.1%% CAGR |
| Middle East & Africa | 20.1% | 6.1%% CAGR |
Source: Claritas Intelligence — Primary & Secondary Research, 2026.
Baxter International Inc. Otsuka Holdings Co., Ltd. Mead Johnson & Company, LLC Danone Nutricia, Victus, Inc. Abbott Laboratories Pfizer Inc. Bayer AG Nestle S.A. GlaxoSmithKline plc. These major players compete across product innovation, reimbursement relationships, and clinical evidence generation. Baxter demonstrated leadership through smart infusion pump integration with hospital systems, while companies like Danone Nutricia and Abbott focus on disease-specific formulations and sustainable packaging. Market consolidation and strategic partnerships are accelerating as competitors seek to expand geographic reach and enhance AI-driven personalization capabilities.
NEW YORK & NORTHBROOK, Ill. (BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis.
Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medical Branch (UTMB Health) demonstrating the positive impact of smart infusion pump integration with hospital electronic medical records (EMRs) on patient safety, clinicians' bedside productivity and programming compliance. The analyses of more than one million infusions on Baxter's Spectrum IQ large volume infusion pumps (LVP) at UTMB were presented at the American Society of Health-System Pharmacists (ASHP) 2025 Midyear Clinical Meeting, held Dec. 7 – Dec. 10, 2025.
The oral clinical nutrition market was valued at USD 18.32 billion in 2025 and is projected to reach USD 29.45 billion by 2033. This represents significant growth in the medical nutrition therapy sector, driven by increasing healthcare expenditures and rising prevalence of disease-related malnutrition across developed and emerging markets. See our market size analysis → See our emerging opportunities →
The oral clinical nutrition market is expanding at a compound annual growth rate (CAGR) of 5.36 percent from 2026 to 2033. Key growth drivers include integration of oral nutritional supplements into standard hospital care pathways, growing awareness of medical nutrition therapy benefits, and increasing focus on reducing hospital readmission rates through proactive therapeutic nutrition interventions. See our growth forecast → See our key growth drivers →
Oral nutritional supplements (ONS) represent the largest segment within the clinical nutrition market, playing a crucial role in addressing disease-related malnutrition across hospital and outpatient care settings. This segment is expected to maintain market leadership through 2033 due to its established therapeutic efficacy and broad clinical applications in recovery protocols. See our segment analysis → See our competitive landscape →
North America is the largest regional market for oral clinical nutrition products, driven by advanced healthcare infrastructure and high adoption of medical nutrition therapy. However, Asia-Pacific is the fastest-growing region with a CAGR of 6.7 to 8.2 percent, attributed to rising healthcare spending, increasing geriatric populations, and expanding hospital networks in emerging economies. See our growth forecast → See our emerging opportunities →
Leading companies in the oral clinical nutrition market include Baxter International Inc., Otsuka Holdings Co. Ltd., Mead Johnson & Company LLC, Danone Nutricia, and Victus Inc. These organizations dominate through extensive product portfolios, strong distribution networks, and continuous innovation in medical nutrition therapy formulations. See our competitive landscape →
Primary growth drivers include increasing prevalence of disease-related malnutrition, aging global populations requiring therapeutic nutrition interventions, and healthcare systems' focus on shortening hospital stays through proactive nutritional management. Additionally, clinical evidence supporting oral nutritional supplements in improving patient recovery outcomes is accelerating adoption across institutional care settings. See our key growth drivers →
Key challenges include high cost barriers to patient access, stringent regulatory requirements across different markets, and competition from alternative nutrition delivery methods. Additionally, limited reimbursement coverage in some regions and the need for continued clinical validation of newer formulations may restrain market expansion in price-sensitive healthcare environments. See our market challenges → See our geography analysis →
Significant opportunities include AI-driven personalized nutrition therapy development, expansion into underserved Asian and Latin American markets, and integration of digital health monitoring with oral nutritional supplement management. Furthermore, growing investment in disease-specific nutrition formulations and the shift toward preventive nutrition care models present substantial growth avenues through 2033. See our emerging opportunities →
How this analysis was conducted
Primary Research
Secondary Research
Access detailed analysis, data tables, and strategic recommendations.